Prevalence of methylenetetrahydrofolate reductase C677T and A1298C polymorphisms in Egyptian patients with type 2 diabetes mellitus

Egyptian Journal of Medical Human Genetics

Volumn 14, Issue 1, 2013, Pages 87-93

  AbdRaboh, Naglaa Raafat ^a   Badr, Soheir ^a   Ali, Samia ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

(MTHFR) gene; Gene polymorphism; Risk factor; T2DM

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); CHOLESTEROL; CREATININE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; UREA;

ADULT; ARTICLE; CONTROLLED STUDY; DIABETIC PATIENT; DNA POLYMORPHISM; EGYPT; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POLYMERASE CHAIN REACTION; PREVALENCE;

EID: 84891688011     PISSN: 11108630     EISSN: 20902441     Source Type: Journal    
DOI: 10.1016/j.ejmhg.2012.09.002     Document Type: Article

References (43)

1. King H., Aubert R.E., Herman W.H. Global burden of diabetes 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998, 21:1414-1431.
2. Sameer N.S., El-Atat F.A., Sowers J.R. Pathogenesis of hypertension in diabetes. Rev Endocr Metab Disord 2004, 5:221-225.
3. Van Ittersum F.J., de Man A.M., Thijssen S., et al. Genetic polymorphisms of the renin-angiotensin system and complications of insulin-dependent diabetes mellitus. Nephrol Dial Transplant 2000, 15:1000-1007.
4. Jeunemaitre X., Soubrier F., Kotelevtsev Y.V., et al. Molecular basis of human hypertension: role of angiotensinogen. Cell 1992, 71:169-180.
5. Doria A., Onuma T., Gearin G., et al. Angiotensinogen polymorphism M235T, hypertension, and nephropathy in insulin-dependent diabetes. Hypertension 1996, 27:1134-1139.
6. Gardemann A., Stricker J., Humme J., et al. Angiotensinogen T174 M and M235T gene polymorphism are associated with the extent of coronary atherosclerosis. Atherosclerosis 1991, 145:309-314.
7. Keane W.F., Eknoyan G. Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): a position paper of the National Kidney Foundation. Am J Kidney Dis 1999, 33(5):1004-1010.
8. Doupis J., Eleftheriadou I., Kokkinos A., et al. Acute hyperhomocysteinemia impairs endothelium function in subjects with type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2010, 118:453-458.
9. Shimomura T., Anan F., Umeno Y., et al. Hyperhomocysteinaemia is a significant risk factor for white matter lesions in Japanese type 2 diabetic patients. Eur J Neurol 2008, 15:289-294.
10. Aso Y., Yoshida N., Okumura K., et al. Coagulation and inflammation in overt diabetic nephropathy: association with hyperhomocysteinemia. Clin Chim Acta 2004, 348:139-145.
11. Buysschaert M., Dramais A.S., Wallemacq P.E., et al. Hyperhomocysteinemia in type 2 diabetes: relationship to macroangiopathy, nephropathy, and insulin resistance. Diabetes Care 2000, 23:1816-1822.
12. Sun J., Xu Y., Zhu Y., et al. Methylenetetrahydrofolate reductase gene polymorphism, homocysteine and risk of macroangiopathy in type 2 diabetes mellitus. J Endocrinol Invest 2006, 29:814-820.
13. Mtiraoui N., Ezzidi I., Chaieb M., et al. MTHFR C677T and A1298C gene polymorphisms and hyperhomocysteinemia as risk factors of diabetic nephropathy in type 2 diabetes patients. Diabetes Res Clin Pract 2007, 75:99-106.
14. Ukinc K., Ersoz H.O., Karahan C., et al. Methyltetrahydrofolate reductase C677T gene mutation and hyperhomocysteinemia as a novel risk factor for diabetic nephropathy. Endocrine 2009, 36:255-261.
15. Kalin A., Alatas O., Colak O. Relation of plasma homocysteine levels to atherosclerotic vascular disease and inflammation markers in type 2 diabetic patients. Eur J Endocrinol 2008, 158:47-52.
16. Alam M.A., Husain S.A., Narang R., et al. Association of polymorphism in the thermolabile 5, 10-methylene tetrahydrofolate reductase gene and hyperhomocysteinemia with coronary artery disease. Mol Cell Biochem 2008, 310:111-117.
17. Frosst P., Blom H.J., Milos R., et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995, 10:111-113.
18. Weisberg I.S., Jacques P.F., Selhub J., et al. The 1298A→C polymorphism in methylenetetrahydrofolate reductase (MTHFR): in vitro expression and association with homocysteine. Atherosclerosis 2001, 156:409-415.
19. Pepe G., Camacho Vanegas O., Giusti B., et al. Heterogeneity in world distribution of the thermolabile C677T mutation in 5,10-methylenetetrahydrofolate reductase. Am J Hum Genet 1998, 63:917-920.
20. Yamada K., Chen Z., Rozen R., Matthews R.G. Effects of common polymorphisms on the properties of recombinant human methylenetetrahydrofolate reductase. Proc Natl Acad Sci USA 2001, 98:14853-14858.
21. McManus R.J., Caulfield M., Williams B., et al. NICE hypertension guideline 2011: evidence based evolution. BMJ 2012, 344:e181.
22. American Diabetes Association Diagnosis and Classification of Diabetes Mellitus. Diabetes Care, 2010; 33(1): S62-S69.
23. Van der Put N.M.J., Gabreels F., Stevens E.M.B. A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects?. Am J Hum Genet 1998, 62:1044-1051.
24. Wang J.G., Staessen J.A. Genetic polymorphisms in the renin-angiotensin system: relevance for susceptibility to cardiovascular disease. Eur J Pharmacol 2000, 410:289-302.
25. Rozen R. Molecular genetics of methylenetetrahydrofolate reductase deficiency. J Inherit Metab Dis 1996, 19:589-594.
26. Movva S., Alluri R.V., Venkatasubramanian S., Vedicherla B., Vattam K.K., Ahuja Y.R., et al. Association of methylene tetrahydrofolate reductase C677T genotype with type 2 diabetes mellitus patients with and without renal complications. Genet Test Mol Biomarkers 2011, 15(4):257-261.
27. Moczulski D., Fojcik H., Zukowska-Szczechowska E., et al. Effects of the C677T and A1298C polymorphisms of the MTHFR gene on the genetic predisposition for diabetic nephropathy. Nephrol Dial Transplant 2003, 18:1535-1540.
28. Sun J., Xu Y., Xue J., et al. Methylenetetrahydrofolate reductase polymorphism associated with susceptibility to coronary heart disease in Chinese type 2 diabetic patients. Mol Cell Endocrinol 2005, 229:95-101.
29. AboElAsrar M.A., Hamed A.A., Akar N., Egin Y., Saied M.M.M. Methylenetetrahydrofolate reductase gene polymorphism in type 1 diabetes mellitus: Relationship to microvascular complications. Egypt J Med Hum Genet 2012, 13(2):139-146.
30. Chang Y.H., Fu W.M., Wu Y.H., Yeh C.J., Huang C.N., Shiau M.Y. Prevalence of methylenetetrahydrofolate reductase C677T and A1298C polymorphisms in Taiwanese patients with Type 2 diabetic mellitus. Clin Biochem 2011, 44(17-18):1370-1374.
31. Koubaa N., Nakbi A., Smaoui M., et al. Hyperhomocysteinemia and elevated ox-LDL in Tunisian type 2 diabetic patients. Role of genetic and dietary factors. Clin Biochem 2007, 40:1007-1014.
32. Mehri S., Koubaa N., Nakbi A., et al. Relationship between genetic polymorphisms of angiotensin-converting enzyme and methylenetetrahydrofolate reductase as risk factors for type 2 diabetes in Tunisian patients. Clin Biochem 2010, 43:259-266.
33. Benes P., Kanková K., Muzi{dotless}́k J., et al. Coronary artery disease, and essential hypertension in the Czech population. Mol Genet Metab 2001, 73:188-195.
34. Eroglu Z., Erdogan M., Tetik A., et al. The relationship of the methylenetetrahydrofolate reductase C677T gene polymorphism in Turkish type 2 diabetic patients with and without nephropathy. Diabetes Metab Res Rev 2007, 23:621-624.
35. Sun J., Xu Y., Zhu Y., et al. Genetic polymorphism of methylenetetrahydrofolate reductase as a risk factor for diabetic nephropathy in Chinese type 2 diabetic patients. Diabetes Res Clin Pract 2004, 64:185-190.
36. Ndrepepa G., Kastrati A., Braun S., et al. Circulating homocysteine levels in patients with type 2 diabetes mellitus. Nutr Metab Cardiovasc Dis 2008, 18:66-73.
37. Helfenstein T., Fonseca F.A., Relvas W.G., et al. Prevalence of myocardial infarction is related to hyperhomocysteinemia but not influenced by C677T methylenetetrahydrofolate reductase and A2756G methionine synthase polymorphisms in diabetic and non-diabetic subjects. Clin Chim Acta 2005, 355:165-172.
38. Fletcher O., Kessling A.M. MTHFR association with arteriosclerotic vascular disease?. Hum Genet 1998, 103:11-21.
39. Cugini P., Baldoni F., De Rosa R., et al. Higher blood pressure load (baric impact) in normotensives with endothelial dysfunction. a paraphysiological status of ''pre-hypertension''. Clin Ter 2002, 153:309-315.
40. Benrahma H., Abidi O., Melouk L., Ajjemami M., Rouba H., Chadli A., et al. Association of the C677T Polymorphism in the Human Methylenetetrahydrofolate Reductase (MTHFR) Gene with the Genetic Predisposition for Type 2 Diabetes Mellitus in a Moroccan Population. Genet Test Mol Biomarkers 2012, 16(5):383-387.
41. Szczeklik A., Sanak M., Jankowski M., et al. Mutation A1298C of methylenetetrahydrofolate reductase. Risk for early coronary disease not associated with hyperhomocysteinemia. Am J Med Genet 2001, 101:36-39.
42. Moczulski D., Fojcik H., Zukowska-Szczechowska E., et al. Effects of the C677T and A1298C polymorphisms of the MTHFR gene on the genetic predisposition for diabetic nephropathy. Nephrol Dial Transplant 2003, 18:1535-1540.
43. Friedman G., Goldschmidt N., Friedlander Y., Ben-Yehuda A., Selhub J., Babaey S., et al. A common mutation A1298C in human methylenetetrahydrofolate reductase gene: association with plasma total homocysteine and folate concentration. J Nutr 2001, 129:1656-1661.